Anixa Biosciences
91 articles with Anixa Biosciences
-
Anixa Biosciences Announces Presentation on Breast Cancer Vaccine Trial at the 2023 AACR Annual Meeting
3/27/2023
Anixa Biosciences, Inc. today announced a presentation on results of its Phase 1a breast cancer vaccine trial on April 17, 2023, at the 2023 American Association for Cancer Research (AACR) Annual Meeting.
-
Anixa Biosciences Reassures Shareholders It Has No Accounts at Silicon Valley Bank
3/13/2023
Anixa Biosciences, Inc. today reassured its shareholders and the investment community that it does not have any accounts at recently collapsed Silicon Valley Bank.
-
Anixa Biosciences to Provide Corporate Update at its 2023 Annual Meeting of Stockholders
3/2/2023
Anixa Biosciences, Inc. today announced that its CEO, Dr. Amit Kumar , will provide a corporate presentation on the company.
-
Anixa Biosciences Announces Notice of Allowance of Additional Key Patent on Breast Cancer Vaccine Technology
2/27/2023
Anixa Biosciences, Inc. today announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance broadening protection of Anixa's novel breast cancer vaccine technology.
-
Anixa Biosciences Announces Formation of Breast Cancer Clinical Advisory Board
2/21/2023
Anixa Biosciences, Inc. today announced the formation of its Breast Cancer Clinical Advisory Board comprising preeminent experts across the breast cancer research and clinical development fields.
-
Anixa Biosciences to Present at Biotech Showcase 2023
12/19/2022
Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that it will present at the Biotech Showcase 2023 conference being held in-person on January 9-11, 2023, at the Hilton San Francisco Union Square in San Francisco, California, and virtually on January 18-19, 2023.
-
Anixa Biosciences Announces Maximum Tolerated Dose Reached in Trial of Preventative Breast Cancer Vaccine
12/8/2022
Anixa Biosciences, Inc. today announced the maximum tolerated dose (MTD) has been reached in the Phase 1a trial of its preventative breast cancer vaccine.
-
Anixa Biosciences Announces Presentation on Breast Cancer Vaccine Trial at the 2022 San Antonio Breast Cancer Symposium
11/8/2022
Anixa Biosciences, Inc. today announced a presentation outlining the design of its ongoing breast cancer vaccine trial on December 7, 2022 , at the 2022 San Antonio Breast Cancer Symposium.
-
Dr. Jose Conejo-Garcia, Invited to Present Keynote Address at Duke Cancer Institute, will Discuss Anixa Biosciences' Ovarian Cancer CAR-T Therapy
10/31/2022
Anixa Biosciences, Inc. today announced that the inventor of its ovarian cancer CAR-T technology, Dr. Jose Conejo-Garcia, has been invited to be the keynote speaker at Duke Cancer Institute's Immuno-Oncology Research Program Retreat on November 4, 2022.
-
Anixa Biosciences Announces Commencement of Phase 1b Trial of its Breast Cancer Vaccine at Cleveland Clinic
10/26/2022
Anixa Biosciences, Inc. today announced the initiation of a Phase 1b trial for its preventative breast cancer vaccine.
-
Anixa Biosciences Announces Presentation on Ovarian Cancer CAR-T Therapy Trial at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
10/10/2022
Anixa Biosciences, Inc. today announced a presentation outlining its ovarian cancer CAR-T therapy trial at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting being held November 8-12, 2022.
-
Anixa Biosciences' Ovarian Cancer CAR-T Therapy to be Presented at the Rivkin Center & American Association of Cancer Research (AACR) 14th Biennial Ovarian Cancer Research Symposium
9/12/2022
Anixa Biosciences, Inc. today announced that the inventor of its ovarian cancer CAR-T technology, Dr. Jose Conejo-Garcia, Senior Member of the Immunology Department at Moffitt Cancer Center, will be speaking at the Rivkin Center and American Association for Cancer Research (AACR) 14th Biennial Ovarian Cancer Research Symposium.
-
Anixa Biosciences to Present at the H.C. Wainwright 24th Annual Global Investment Conference
8/31/2022
Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that it will present a company update at the H.C. Wainwright 24th Annual Global Investment Conference being held September 12-14, 2022 (Hybrid Conference).
-
Novartis' canakinumab failed again in non-small cell lung cancer while Anixa Biosciences, Palisade Bio and Genexine kicked off new trials.
-
Anixa Biosciences Announces Treatment of First Patient in its Ovarian Cancer CAR-T Clinical Trial
8/15/2022
Anixa Biosciences, Inc. today announced that, in conjunction with its partner Moffitt Cancer Center, it has commenced treatment of the first patient in the clinical trial of its novel chimeric antigen receptor T-cell (CAR-T) therapy for ovarian cancer.
-
Anixa Biosciences Announces Notice of Allowance of Additional Patent on Breast Cancer Vaccine Technology
7/21/2022
Anixa Biosciences, Inc. (NASDAQ: ANIX) ("Anixa"), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance broadening protection of Anixa's novel breast cancer vaccine technology.
-
Anixa Biosciences Announces Publication of Peer-Reviewed Journal Article in Clinical and Experimental Vaccine Research Highlighting Ovarian Cancer Vaccine Technology
6/21/2022
Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced the publication of a peer-reviewed journal article in Clinical and Experimental Vaccine Research.
-
Anixa Biosciences to Present at the 2022 H.C. Wainwright Global Investment Conference
5/5/2022
Anixa Biosciences, Inc. today announced that it will present a company update at the H.C. Wainwright Global Investment Conference being held May 23-26, 2022 (Hybrid Conference).
-
Anixa Biosciences Announces Presentation on Breast Cancer Vaccine Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting
4/28/2022
Anixa Biosciences, Inc. today announced a presentation outlining the design of its breast cancer vaccine trial at the American Society of Clinical Oncology (ASCO) Annual Meeting being held June 3-7, 2022.
-
Anixa Biosciences' Ovarian Cancer CAR-T Therapy to be Discussed at The 4th International Workshop on CAR-T 2022
4/6/2022
Anixa Biosciences, Inc. today announced that the inventor of its ovarian cancer CAR-T technology, Dr. José Conejo-Garcia, Chair of the Immunology Department at Moffitt Cancer Center, will be presenting at The 4th International Workshop on CAR-T (iwCAR-T) 2022 on Friday, April 29, 2022.